Fri, Jul 25, 2014, 11:15 AM EDT - U.S. Markets close in 4 hrs 45 mins

Recent

% | $
Click the to save as a favorite.

Dendreon Corp. Message Board

  • dinepat203 dinepat203 Mar 27, 2013 2:37 PM Flag

    When Trading desk guy reverse the trade meaning short covering started !

    Time to get inn....before June. No options available for June July meaning EMA approval due in June.
    By May end this should be $15 ..$25

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Evidently you don't know how options work? June's options become available on the first trading day after April expiry.

    • 180 days opinion from CHMP will discuss Provenge during their meeting- 180 DAYS falls within March 2013 meeting.

    • September 27, 2012--Dendreon Corporation (NASDAQ:DNDN) today announced the first patient enrollment and initiation of treatment for the sipuleucel-T European Union (EU) open-label study. The open-label study is being conducted in European men with metastatic castrate-resistant prostate cancer (mCRPC) to describe product release parameters and report on safety in a European population. The study may enroll up to 45 patients in four sites across the EU. Dendreon has submitted a marketing authorization application (MAA) for sipuleucel-T which is currently under review by the European Medicines Agency (EMA). Sipuleucel-T is not approved for use outside the U.S. Sipuleucel-T is approved by the Food and Drug Administration (FDA) in the U.S. for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. It is marketed under the name PROVENGE®.

      "We are extremely pleased with the progress of this new study and that the first patient has begun his treatment," said Thomas Powles MD, MRCP, Barts Cancer Institute, St. Bartholomew's Hospital, London. "We are also excited about the potential study outcomes and look forward to a successful program with the support of our committed clinical team and dedicated patients."

      In addition to the current EU open-label study, the following data presentations are taking place at the ESMO 2012 Congress in Vienna, Austria, 28 September —2 October:
      •Saturday, September 29, 13:00-14:00 CEST — Abstract #939P: "Neoadjuvant Sipuleucel-T in Localized Prostate Cancer: Effects on Immune Cells within the Prostate Tumor Microenvironment." Poster presentation.
      •Saturday, September 29, 13:00-14:00 CEST — Abstract #940P: "Overall Survival Benefit with Sipuleucel-T by Baseline PSA: An Exploratory Analysis from Three Phase 3 Trials." Poster presentation.
      •Saturday, September 29, 13:00-14:00 CEST — Abstract #941P: "Impact of Salvage Therapy with AC8015F on the Overall Survival Benefit Achieved with Sipuleucel-T

    • Bulls are returning on DNDN ..normally pigs gets crushed to avoid stamped go through the safety instructions carefully.
      1. If you have shorted you will have to cover asap.
      2. If you are LONG but profit oriented -DO NOT SELL during action scene , wait for dust to settle. You might sell this cheap .

    • Europe has been fast-tracking proven drugs like this. If you think approval may not happen until June or July,
      you may be late to the game.

    • DTC is sleeping or Hand in Gloves with hedge

 
DNDN
2.1701-0.0199(-0.91%)11:14 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.